These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 6677463)

  • 1. Tissue doses in man: implications in risk assessment.
    Golkar SO
    Dev Toxicol Environ Sci; 1983; 11():289-98. PubMed ID: 6677463
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular dosimetry techniques in human risk assessment: an industrial perspective.
    Wright AS
    Dev Toxicol Environ Sci; 1983; 11():311-8. PubMed ID: 6329628
    [No Abstract]   [Full Text] [Related]  

  • 3. Macro molecular dosimetry.
    Lee WR
    Dev Toxicol Environ Sci; 1983; 11():281-8. PubMed ID: 6428848
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative chemical mutagenesis on the basis of molecular dosimetry.
    Tates AD
    Prog Clin Biol Res; 1982; 109():21-34. PubMed ID: 7167543
    [No Abstract]   [Full Text] [Related]  

  • 5. Macromolecule adducts, target dose and risk assessment.
    Ehrenberg L; Osterman-Golkar S; Törnqvist M
    Prog Clin Biol Res; 1986; 209B():253-60. PubMed ID: 3749083
    [No Abstract]   [Full Text] [Related]  

  • 6. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
    Lutz WK
    Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending the threshold of regulation concept: de minimis limits for carcinogens and mutagens.
    Fiori JM; Meyerhoff RD
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):209-16. PubMed ID: 12052005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of the protective effect of garlic extract and cell defense during adaptive response].
    Vasil'eva IM; Zasukhina GD
    Genetika; 2002 Mar; 38(3):422-5. PubMed ID: 11963572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of in vivo mutation data can inform cancer risk assessment.
    Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA adduct formation and T lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene.
    Beland FA
    Res Rep Health Eff Inst; 1995 Oct; (72):1-27; discussion 29-39. PubMed ID: 11381742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of genetic risks of alkylating agents. III. Alkylation of haemoglobin after metabolic conversion of ethene to ethene oxide in vivo.
    Ehrenberg L; Osterman-Golkar S; Segerbäck D; Svensson K; Calleman CJ
    Mutat Res; 1977 Nov; 45(2):175-84. PubMed ID: 593285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
    Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
    Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
    Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
    Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in toxicology and risk assessment: informing critical dose-response relationships by Swenberg et al., 2008.
    Keshava N; Chen C; White P; Sonawane B; Bussard D
    Chem Res Toxicol; 2009 Jan; 22(1):8-10; author reply 10-2. PubMed ID: 19053183
    [No Abstract]   [Full Text] [Related]  

  • 16. General 4-week toxicity study with EMS in the rat.
    Pfister T; Eichinger-Chapelon A
    Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Approaches to assessing the human risk of mutagens].
    Zhurkov VS; Sycheva LP; Revazova IuA; Novikova SM
    Gig Sanit; 2006; (5):23-4. PubMed ID: 17087204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risk assessment for crotonaldehyde and 2-hexenal: an approach.
    Eder E; Schuler D; Budiawan
    IARC Sci Publ; 1999; (150):219-32. PubMed ID: 10626223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Decreased survivability and a DNA repair defect in the cells of patients with xeroderma pigmentosum and Cockayne syndrome under the action of radiation and chemical mutagens].
    Spivak IM; Pleskach NM; Mikhel'son VM; Bootsma D; Kolman A
    Tsitologiia; 1997; 39(6):420-34. PubMed ID: 9381559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung cancer risk in mice: analysis of fractionation effects and neutron RBE with a biologically motivated model.
    Heidenreich WF; Carnes BA; Paretzke HG
    Radiat Res; 2006 Nov; 166(5):794-801. PubMed ID: 17067205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.